Aurobindo Pharma Share Price Falls 5% After USFDA Classifies Eugia Unit as OAI

Aurobindo Pharma share price down over 5% on June 15. Eugia Unit-III OAI after Jan-Feb 2026 USFDA inspection. 11 observations. 52W high Rs 1,550.

Aurobindo Pharma share price declined over 5% on June 15, 2026, as markets continued to react to the USFDA’s classification of Eugia Unit-III, a formulation manufacturing facility of wholly-owned subsidiary Eugia Pharma Specialities Ltd, as Official Action Indicated (OAI). The announcement was made on June 13, 2026, after the regulator reviewed its January-February 2026 inspection at which 11 observations were issued. The OAI is the most serious USFDA inspection outcome and indicates potential regulatory action ahead.

Click Here – Get Free Investment Predictions

USFDA OAI Classification: Full Details of the Eugia Unit-III Inspection

The USFDA conducted a cGMP inspection at Eugia Unit-III from January 27 to February 6, 2026. At conclusion, the regulator issued 11 observations. After reviewing Aurobindo Pharma‘s responses, the USFDA determined the outcome as OAI and the company notified stock exchanges on June 13, 2026. The table below summarises the regulatory event in full.

What OAI Means and Why Aurobindo Pharma Share Price Fell Over 5%

OAI is the most serious of three USFDA inspection classifications. It signals that the regulator found significant objectionable conditions and believes administrative or regulatory sanctions are warranted. For Aurobindo Pharma share price, the OAI raises two concerns.

First, OAI often precedes a USFDA Warning Letter, which can restrict new drug application approvals from the affected facility and potentially trigger import alerts. Second, Eugia Unit-III has a history of serious USFDA scrutiny: it received an OAI in May 2024, followed by a Warning Letter in August 2024. A second OAI cycle within two years at the same facility raises systemic quality management questions.

Ankit Jaiswal, Senior Research Analyst at Univest, notes that Aurobindo Pharma share price had recovered strongly from its 52-week low of Rs 1,016.10 before this regulatory setback. He flags that the key question for investors is whether the USFDA will issue a Warning Letter as a follow-up to this OAI, which would be a more material escalation for US revenue from Eugia Unit-III.

Kunal Singla, Associate Director at Univest, observes that Aurobindo’s diversified multi-facility manufacturing base means a single facility OAI does not threaten overall US revenues. However, the repetitive nature of serious compliance observations at Eugia Unit-III specifically warrants close monitoring of the USFDA’s subsequent enforcement steps.

Track live Aurobindo Pharma share price and pharma regulatory news on the Univest Screener

Aurobindo Pharma Financial Performance and US Market Exposure

Aurobindo Pharma reported FY26 total revenues of Rs 33,384 crore, up 6.39% year on year. The US accounts for approximately 40 to 45 percent of consolidated revenues. Eugia Pharma Specialities operates multiple manufacturing units, and the company has historically managed USFDA classification issues through comprehensive corrective action plans submitted post-inspection.

The company stated in its exchange filing that it is committed to maintaining the highest quality manufacturing standards at all facilities globally. The 11 inspection observations at Eugia Unit-III and the USFDA’s decision to classify them as OAI suggest the responses to those observations were considered insufficient at this stage.

Download the Univest iOS App or Univest Android App to track Aurobindo Pharma share price live and monitor pharma regulatory news.

Conclusion

Aurobindo Pharma share price fell over 5% on June 15, 2026, after the USFDA classified Eugia Unit-III as OAI following a January-February 2026 inspection with 11 observations. This is the most serious USFDA inspection outcome and raises the risk of further regulatory escalation including a potential Warning Letter, as happened previously at the same facility in 2024. Ankit Jaiswal and Kunal Singla at Univest recommend monitoring whether the USFDA issues a Warning Letter as the next critical trigger for Aurobindo Pharma share price direction.

Frequently Asked Questions

Why did Aurobindo Pharma share price fall on June 15, 2026?

Ans. Aurobindo Pharma share price fell over 5% on June 15, 2026, after the USFDA classified Eugia Unit-III, a formulation manufacturing facility of Eugia Pharma Specialities, as OAI. The OAI classification was disclosed on June 13, 2026, and the market continued to react on June 15 as investors assessed the potential regulatory escalation.

What is OAI classification and what does it mean for Aurobindo Pharma?

Ans. OAI stands for Official Action Indicated. It is the most serious of three USFDA inspection outcomes: NAI (No Action Indicated), VAI (Voluntary Action Indicated), and OAI. OAI means the USFDA found significant objectionable conditions and administrative or regulatory action is indicated, which can include Warning Letters or import alerts.

What is Eugia Pharma Specialities and which facility received the OAI?

Ans. Eugia Pharma Specialities Ltd is a wholly-owned subsidiary of Aurobindo Pharma. The OAI classification was for its Unit-III facility, a formulation manufacturing plant at Pashamylaram, Sangareddy District, Telangana. The USFDA inspected this facility from January 27 to February 6, 2026, issuing 11 observations.

How many observations did the USFDA issue at Eugia Unit-III?

Ans. The USFDA issued 11 observations at the conclusion of its inspection of Eugia Unit-III, conducted from January 27 to February 6, 2026. The nature and number of these observations led the regulator to classify the facility as OAI after reviewing the company’s responses.

Has Aurobindo Pharma’s Eugia Unit-III faced OAI classification before?

Ans. Yes. Eugia Unit-III previously received an OAI classification in May 2024. That classification was subsequently followed by a USFDA Warning Letter in August 2024. The current OAI relates to a fresh inspection cycle in early 2026 and is a separate regulatory event.

What is the potential impact of the OAI on Aurobindo Pharma’s US business?

Ans. An OAI classification can lead to a Warning Letter, import alerts, or restrictions on new drug application approvals from the affected facility. Aurobindo Pharma has stated it is committed to maintaining the highest quality standards and will work closely with the USFDA to address the inspection findings comprehensively.

What is Aurobindo Pharma’s financial performance?

Ans. Aurobindo Pharma reported FY26 total revenues of Rs 33,384 crore, up 6.39% year on year from Rs 31,378 crore in FY25. The US is the company’s largest single revenue contributor. The company is one of India’s leading generic pharmaceutical exporters with operations across multiple facilities in India, the US, and Europe.

Should I sell Aurobindo Pharma shares after the OAI news?

Ans. Investment decisions on Aurobindo Pharma share price should consider the severity of the OAI findings, the remediation timeline, and potential impact on US revenue from Eugia Unit-III. OAI classifications have been resolved by companies with corrective action plans in the past. Always consult a SEBI-registered investment adviser before acting on regulatory news.